-

Verily and Swiss Re Broaden Strategic Relationship

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verily and Swiss Re today announced they have closed a transaction whereby Swiss Re exchanged its investment in Granular Insurance Company (“Granular”) for an equity stake in Verily. Granular is now wholly-owned by Verily.

“During our two-year relationship, we’ve been able to show Swiss Re our vision for how Verily can impact precision health,” said Andy Conrad, Chief Executive Officer, Chairman, and Founder of Verily. “We welcome Swiss Re and their expertise to our group of investors who see the potential of Verily to impact the larger healthcare ecosystem.”

Swiss Re is one of the world’s leading providers of reinsurance, insurance and other forms of insurance-based risk transfer and solutions. In 2020, it made a minority investment in Granular, an insurer that provides self-funded employers with a data-based approach to help them manage risks, costs and achieve better outcomes. Swiss Re will no longer be a direct shareholder in Granular, nor directly involved in its operations. Both Granular and Swiss Re remain independently committed to the Employer Stop Loss segment in the United States.

“We are pleased to broaden our strategic relationship with Verily,” said Christian Mumenthaler, Chief Executive Officer of Swiss Re. “Our positive experience collaborating with Verily over the last two years has given us confidence in expanding the relationship towards potential new areas of innovation in the life and health space.”

About Verily

Verily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered. Launched from X in 2015, Verily’s purpose is to bring the promise of precision health to everyone, every day. Verily is focused on generating and activating data from a wide variety of sources, including clinical, social, behavioral and the real world, to arrive at the best solutions for a person based on a comprehensive view of the evidence. Verily uses its recognized expertise and capabilities in technology, data science and healthcare to enable the entire healthcare ecosystem to drive better health outcomes. For more information, please visit verily.com.

Contacts

For Media Inquiries:
Steven Cooper, Verily
sjcoop@verily.com

Verily


Release Versions

Contacts

For Media Inquiries:
Steven Cooper, Verily
sjcoop@verily.com

More News From Verily

Verily Accelerates Precision Health AI With NVIDIA

DALLAS--(BUSINESS WIRE)--Verily, a precision health AI company, today announced a collaboration with NVIDIA to integrate NVIDIA’s AI technology stack into its Pre platform, which is used by health system, life science, payer, and government customers and partners to more efficiently develop and deploy AI across healthcare. Verily has added NVIDIA’s GPU-accelerated libraries and frameworks, including NVIDIA NeMo, NVIDIA Parabricks, and NVIDIA CUDA-X Data Science within Workbench, Verily’s truste...

Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025

DALLAS--(BUSINESS WIRE)--Verily, a precision health AI company, today announced the launch of a new consumer health app, Verily Me, that will be featured at HLTH USA 2025. Verily Me is designed to close gaps in care and enable people to stay informed and engaged in their health journey over time. Within the app, users can: Get personalized recommendations from providers: Licensed clinicians review relevant patient records across multiple providers and health systems and provide health recommend...

Verily, UCHealth, University of Colorado Anschutz, and RefinedScience Launch Strategic Collaboration for AI-Powered Research and Care Transformation

DALLAS--(BUSINESS WIRE)--Verily today announced a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to transform how data is used and care is delivered, supported by Verily’s deep domain expertise and built-for-purpose healthcare technology capabilities. The agreement is grounded in a joint commitment to transform patient care and precision medicine through the latest advancements in artificial intelligence, digital technology and medical...
Back to Newsroom